NEU1 and GM1 gangliosidosis: However, the identification by Wenger et al. of the absence of NEU1 activity, in combination with the partial deficiency of β-GAL in a patient previously classified as having GM1-gangliosidosis, established GS as a new clinical entity, distinct from GM1-gangliosidosis [4].